Development of Bisindole-Substituted Aminopyrazoles as Novel GSK-3β Inhibitors with Suppressive Effects against Microglial Inflammation and Oxidative Neurotoxicity
作者:Jian-Guo Liu、Danfeng Zhao、Qi Gong、Fengxia Bao、Wen-Wen Chen、Haiyan Zhang、Ming-Hua Xu
DOI:10.1021/acschemneuro.0c00520
日期:2020.10.21
kinase-3β (GSK-3β) inactivation-centric agents with polypharmacological profiles is increasingly recognized as a promising therapeutic strategy against the multifactorial etiopathology of Alzheimer’s disease (AD). In this respect, a series of disubstituted aminopyrazole derivatives were designed and synthesized as a new class of GSK-3β inhibitors. Most of these derivatives possess GSK-3β inhibitory activities
开发具有多种药理学特征的以糖原合酶激酶-3β (GSK-3β) 失活为中心的药物越来越被认为是一种有前途的治疗策略,可对抗阿尔茨海默病 (AD) 的多因素病因。在这方面,设计并合成了一系列二取代氨基吡唑衍生物作为一类新的GSK-3β抑制剂。这些衍生物大多具有 GSK-3β 抑制活性,IC 50值在微摩尔范围内,其中双吲哚取代的氨基吡唑衍生物6h表现出中等 GSK-3β 抑制作用(IC 50= 1.76 ± 0.19 μM),以及对脂多糖 (LPS) 诱导的 BV-2 细胞神经胶质炎症和谷氨酸诱导的 HT-22 细胞氧化神经毒性的缓解作用。进一步的体内研究表明,化合物6h具有有效的抗炎作用,通过显示 LPS 注射小鼠脑中的小胶质细胞活化和星形胶质细胞增殖显着降低。总体而言, 6h对疾病网络的多种功能障碍的同时调节突出了这种结构独特的双吲哚取代的氨基吡唑可能是发现新的治疗药物以解决 AD 和其他